8-K: Tarsus Pharmaceuticals Reports Strong XDEMVY Sales, Pipeline Growth

Tarsus Pharmaceuticals, Inc. published a corporate presentation highlighting strong XDEMVY sales, pipeline expansion, and future growth strategies.

Summary

• Tarsus Pharmaceuticals reported XDEMVY net sales of $118.7 million for Q3 2025, representing a 147% year-over-year growth.
• The company provided Q4 2025 net sales guidance of $140-$145 million and full-year 2025 estimated net sales of $440-$445 million for XDEMVY.
• XDEMVY has treated over 500,000 patients to date, with over 20,000 Eye Care Professionals (ECPs) prescribing and weekly prescriptions exceeding 11,000 and growing.
• The company estimates a peak sales potential of over $1 billion for XDEMVY beyond 2026.
• Tarsus initiated a Phase 2 study for TP-04 in ocular rosacea in December 2025, with data expected in 1H 2027.
• Plans are in place to initiate a Phase 2 study for TP-05 for Lyme disease prevention in 2026.
• Global expansion efforts include a New Drug Application for TP-03 in China (accepted), ongoing discussions with Japanese regulators in 2026, and potential regulatory approval for XDEMVY in Europe by 2027.

Sentiment

Score: 9

Explanation: The filing presents a highly positive outlook, driven by exceptional commercial performance of XDEMVY, strong financial guidance, and promising advancements in a robust pipeline targeting large unmet medical needs. The company's strategic vision for category creation and global expansion further enhances the positive sentiment.

Positives

• XDEMVY, the only FDA-approved medicine for Demodex blepharitis, demonstrates strong commercial success with significant year-over-year net sales growth of 147% in Q3 2025.
• The company projects substantial future growth for XDEMVY, with estimated peak sales potential exceeding $1 billion beyond 2026.
• High market penetration is evidenced by over 20,000 ECPs prescribing XDEMVY and over 500,000 patients treated since launch.
• The direct-to-consumer (DTC) campaign is delivering positive and growing ROI, with a 42% year-over-year increase in website visits and 90% unaided Demodex blepharitis awareness.
• The pipeline includes two promising investigational therapies: TP-04 for ocular rosacea (Phase 2 initiated) and TP-05 for Lyme disease prevention (Phase 2 planned), both utilizing the Lotilaner molecule with demonstrated safety profiles.
• Strong intellectual property protection is in place for XDEMVY (patents through 2038), TP-04 (through at least 2038), and TP-05 (through at least 2040).
• Broad payer coverage for XDEMVY, covering over 90% of commercial, Medicare, and Medicaid lives, ensures patient access.

Risks

• The potential commercial success and growth of XDEMVY, including market size, acceptance, demand, adoption rate, and peak sales potential, are subject to risks and uncertainties.
• Ability to maintain distribution and patient access for XDEMVY, as well as the timing and breadth of payer coverage, may impact financial results.
• Expanding the clinical applications of XDEMVY in eye care and the successful execution of the sales force and direct-to-consumer campaigns are not guaranteed.
• The timing, objectives, and results of clinical trials for pipeline candidates (Lyme disease prevention, ocular rosacea) and their potential market size and opportunity are uncertain.
• Anticipated regulatory and development milestones, including the clarity of the regulatory path forward for TP-04 and TP-05 in the US, and potential Europe, Japan, and China regulatory pathways and approval for XDEMVY/TP-03, involve inherent risks.
• The ability to continue investing in the business, add new programs, create value, and become an eye care leader depends on various factors and market conditions.

Future Outlook

Tarsus Pharmaceuticals anticipates continued strong growth for XDEMVY, projecting it to achieve blockbuster-plus status with over $1 billion in peak sales beyond 2026. The company plans to expand its pipeline by adding 1-2 new programs annually, with key milestones including Phase 2 data for ocular rosacea (TP-04) in 1H 2027 and the initiation of a Phase 2 study for Lyme disease prevention (TP-05) in 2026. Global expansion for XDEMVY (TP-03) is also a focus, with regulatory approvals targeted for Europe by 2027 and ongoing discussions in Japan.

Management Comments

• Tarsus is 'Rewriting the Biotech Playbook' by focusing on category creation and transforming the standard of care for large, unmet disease states.
• The company aims to turn experience into a strategic advantage, moving from unmet need to potential standard of care.
• Management emphasizes 'Delivering Continued Value Creation' through financial strength, discipline, and scalable growth, with a goal to add 1-2 new programs each year.
• The leadership team is 'Poised to Lead the Next Era in Eye Care and Beyond' driven by XDEMVY's exceptional launch and a high-performing commercial engine.

Industry Context

Tarsus Pharmaceuticals is positioning itself as a leader in eye care and beyond, focusing on creating new treatment categories for highly prevalent diseases with unmet needs. XDEMVY's success in Demodex blepharitis, a condition affecting an estimated 25 million Americans, demonstrates the potential for significant market capture by addressing root causes. The pipeline expansion into ocular rosacea (affecting 15-18 million Americans) and Lyme disease prevention (affecting 27 million Americans at risk) aligns with a strategy to target large patient populations where current therapeutic options are limited or non-existent, aiming to establish new standards of care.

Stakeholder Impact

• Shareholders: Potential for significant value creation through strong XDEMVY sales growth, pipeline expansion, and projected blockbuster status.
• Patients: Access to the only FDA-approved treatment for Demodex blepharitis (XDEMVY) and potential future treatments for ocular rosacea (TP-04) and Lyme disease prevention (TP-05).
• Eye Care Professionals (ECPs): New and effective treatment options for prevalent eye conditions, supported by educational campaigns and evidence.
• Employees: Continued growth and expansion could lead to increased opportunities and stability within the company.

Next Steps

• Continue to accelerate XDEMVY progress by increasing ECP utilization and enhancing DTC campaign ROI.
• Expand the clinical applications of XDEMVY in eye care.
• Initiate a Phase 2 study for TP-05 (Lyme disease prevention) in 2026.
• Obtain Phase 2 data for TP-04 (ocular rosacea) in 1H 2027.
• Pursue global expansion for XDEMVY/TP-03, including potential regulatory approval in Europe by 2027 and ongoing discussions in Japan in 2026.
• Potentially add 1-2 new programs to the pipeline each year.

Key Dates

Recommendation

The filing demonstrates exceptional commercial execution for XDEMVY, evidenced by 147% YoY net sales growth in Q3 2025 and a projected $1B+ peak sales potential. The robust financial guidance for FY2025, coupled with a promising pipeline addressing significant unmet medical needs (ocular rosacea, Lyme disease prevention) with strong IP protection, positions Tarsus for sustained long-term growth. The company's strategic focus on category creation and global expansion further de-risks future revenue streams, making it a compelling 'strong buy' for investors seeking growth in the pharmaceutical sector.

Keywords

Tarsus Pharmaceuticals, XDEMVY, Demodex blepharitis, ocular rosacea, Lyme disease prevention, TP-04, TP-05, ophthalmology, biotechnology, pharmaceuticals, eye care, Lotilaner